Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Top 50 Global Stem Cell Influencers Announced
Lanza #4
http://www.terrapinn.com/2013/stemcells/data/top-50-stem-cell-influencers.pdf
press
http://blogs.terrapinn.com/total-biopharma/2013/03/11/top-50-global-stem-cell-influencers-announced/
keywest,
actually the float is closer to 2.25B
Just so everyone is aware, the fees asked for below that were denied is from PRIOR lawsuit A/G had against ACT that ran from Oct of 2007 thru March 18 of 2010. On a motion from A/G case was dismissed one day prior to jury trial. A/G then filed another lawsuit against ACT in August of 2011 that is still pending...
lasers,
No, ACT was denied any legal fees in both civil court and appeals court.
Here is fair read on why..
http://www.law.com/jsp/ca/PubArticleCA.jsp?id=1202498198702&
lasers,
The $3.5MM, imo, falls under disgorgement. These are dollars
ACT received that were illegal. The penalties sometimes can be
as much as the disgorgement. Hopefully it won't be any worse
than the $3.5MM..
SEC relief sought,
II.
Disgorgement
Issue an Order directing Lefkowitz, Compass Capital, Unico, Peacock, Traveller, and Advanced Cell to disgorge, with prejudgment interest, all profits that they received as a result of the acts and/or courses of conduct alleged in this Complaint.
III.
Penalties
Issue an Order directing Lefkowitz, Compass Capital, Lopez, Unico, Peacock, Traveller, and Advanced Cell to pay civil money penalties pursuant to Section 20(d) of the Securities Act [15 U.S.C. § 77t(d)] and Section 21(d) of the Exchange Act [15 U.S.C. § 78u(d)].
lasers,
"and we're now working on finalizing a settlement with the SEC"
as far as when? I don't know, the above statement by Rabin was made
22 days ago.
As far as what the settlement will be? Really don't know. ACT has already expensed the $3.5MM
"The Company expensed the $3.5 million as “fines and penalties” in the consolidated statement of operations and recorded the $3.5 million liability to “loss contingency accrual” in the consolidated balance sheet."
What the total amount actually ends up being is anyones guess...
gas,
bball,
full time job correcting BS here..why is that?..lol
simple,
options were issued on 01/02/2013, closing price on that day was
.0579 therefore that is the exercise price...nothing more to it.
Glad to see you got the right Lincoln this time around, your prior post wasn't...
http://www.corporationwiki.com/Illinois/Chicago/lincoln-park-financial/89187611.aspx
louisa,
yes, hearing tomorrow on A/G case. Hearing is on ACT's 2 motions,
1) to dismiss new claims in A/G's second amended complaint
2) Sanctions against A/G for frivolus claims...
The last time around the Judge took 2 months+ to file a Report from hearing, not sure when we will hear anything. In the scheme of things this case is second fiddle to the SEC case. Sec case needs to be settled in order to qualify for Nasdaq listing. Two weeks ago today Rabin said the following..."and we're now working on finalizing a settlement with the SEC"
per request,
the new OS# as of FEB 14...2,351,603,922...does NOT include the 96MM
shares registered in S-3 yesterday and does NOT include any future shares for Lincoln financing.
the increase of approx 160MM shares would be the 80MM+ that were issued
to CAMOFI and the majority of the remaining 80MM were most like shares to Lincoln for draws...
The S-3 is registering shares for the $6MM CAMOFI debenture. Here is some info from within..
S-3 Filed
http://www.sec.gov/Archives/edgar/data/1140098/000101968713000563/advancedcell_s3-2013.htm
2,351,603,922 shares of our common stock were actually outstanding as of February 14, 2013
160,301,205 share increase since Nov 2,2012
96,401,028 shares of common stock issuable upon conversion of the debentures held by the selling stockholders. In accordance with our agreement with the selling stockholders, we are registering our estimate of all shares of common stock issuable as principal upon conversion of the debentures, assuming all principal payments are made in shares of common stock and the debentures are held until maturity. The issuance of these debentures are described under the heading “Issuance of Securities to Selling Stockholders,” commencing on page 21 of this prospectus.
(1) This assumes 76,040,810 shares of common stock are to be issued to CAMOFI pursuant to the Debentures. As of February 14, 2013, CAMOFI held 48,000,623 shares of our common stock.
(2) This assumes 20,360,218 shares of common stock are to be issued to CAMHZN pursuant to the Debentures. As of February 14, 2013, CAMHZN held 12,853,020 shares of our common stock.
not quite,
approximately 17,696 +/- rentable square feet of office and laboratory space
http://www.sec.gov/Archives/edgar/data/1140098/000101968713000179/advancedcell_8k-ex1005.htm
Wopsal,
Fern,
Gas,
10,544,828..Volume
2,133,100 Form T
don yan,
Lanza sold approx 11.6 million shares in 2012 for about $1.7 million
e-mail question to Rabin with his response from
poster "tmfbmf" on I-cell
Hi Gary. I noticed a discrepancy on the clinicaltrials.gov site:
“There will be 5 cohorts, the 4 low vision cohorts will contain 3 patients, the better vision cohort will contain 4 patients."
In paragraph 2 it says, “Three AMD patients- 50,000 MA09-hRPE cells transplanted Three AMD patients- 100,000 MA09-hRPE cells transplanted Three Better Vision AMD patients- 100,000 MA09-hRPE cells transplanted Three AMD patients- 150,000 MA09-hRPE cells transplanted Three AMD patients- 200,000 MA09-hRPE cells transplanted.”
Is the new cohort 3 or 4 better-vision patients? And will we be injecting better-vision patients with 150k and 200k cells as well?
Thanks!
Best regards,
------------------------
Hi Thomas,
Wow, good catch. I will tell the group that does those protocol changes to fix it. We are doing 4 patients in the new Cohort 2a. We felt that this was enough data given what we are trying to see across all three trials (i.e., it will total 12 additional patients treated with 100,000 cells). We feel that 100,000 cells injected into the area where we are forming the blebs is sufficient given the survival and attachment data we are seeing thus far. This is all to help us better design our treatments for Phase 2 and beyond. Also, we will hopefully be able to see an even greater level of engraftment in retinas with smaller fields of atrophy (as well as the potential for more substantial visual acuity changes). Our Ophthalmic Advisory Board was unanimous in this approach, and as you are aware, they are really the leaders in the field. I must say that the 20/100 patient population (particularly in the AMD) is a bit tricky though. They are at a crossroads where the rate of decline in their vision in the normal course of the disease is relatively rapid as compared to earlier or later onset stages of the disease. So lots of variables.
I hope this answers your questions.
Best,
Gary
lasers,
ACT is NOT in a Phase 2a efficacy trial. Why do you continue
to say that?...
lasers,
It is not a Phase 2a, it is a COHORT 2a...big difference
Biological: Biological: MA09-hRPE Cellular therapy
•Cohort 1 50,000 cells
•Cohort 2 100,000 cells
•Cohort 2a Better Vision 100,000 cells
•Cohort 3 150,000 cells
•Cohort 4 200,000 cells
don yan,
1) Can Camofi demand that the debentures be converted into stock options. If yes, then this could lead to more dilution.
Not "stock options", they can convert to shares of ACT common stock. Dilution? absolutely.
What does Conversion Price mean?
one states 80% of VWAP the other uses "average"..
b)Conversion Price. The conversion price in effect on any Conversion Date shall be equal to 80% of the VWAP of the 10 consecutive Trading Days prior to the Conversion Date (subject to adjustment herein) (the “Conversion Price”).
OR
(ii) 80% of the average of the 10 closing prices immediately prior to the date the quarterly payment is due.
well, todays 8K simply states that 80,357,143 shares of ACT common stock was issued to CAMOFI/CAMHZN per the settlement agreement. These are unregistered shares that are exempt and approved under Section 3(a)(10). These are freely tradeable shares.
The share issuance was part 1 of 3. ACT will need to issue
$2MM in cash yet and register a $6MM 8% convertible debenture
via a registration statement that is forthcoming.
sports,
not sure I understand what you want to know?
2020,
The fairness hearing is scheduled for today. Approval of terms by Court will produce a "court order". Once the court order is granted the shares will be issued under the following terms,
" freely tradable shares of Advanced Cell common stock, payable within two Business Days (as defined below) of the Court Order being granted."
lasers,
Todays PR most likely changed your mind?
crawford,
no, I didn't miss the point, you did. I wasn't addressing
whether it's good or bad they sell shares. You stated the reason
"to survive with no income", which is BS...
crawford,
maybe there is room for improvement on your end too?
In 2011 Rabin received $1.14 million in cash from salary+bonus
In 2011 Lanza received $662,500 in cash from salary and bonus
2012 numbers will be out in March..
Fairness Hearing will be held January 22 to approve
settlement between ACT and Camofi.
https://iapps.courts.state.ny.us/nyscef/ViewDocument?docIndex=RnAIcsMDTL44mA_PLUS_pOt1Cjg==
sports guy and all,
Yesterday ACT announced a settlement with Camofi. Of the "51" warrant holders this was the last one. Aronson/Gorton is not part of this group but remains active along with the SEC case.
None of the material ACT filed yesterday is filed, at least publicly, on the court docket.
1) Has the court approved all this under the 3(a)(10) exemption?
I honestly am not sure but am actually leaning that way.
2) If the court did approve of agreement then the following takes place.
a) $4.5MM worth of freely tradeable shares at approx .056 would be issued within two Business Days after the day they close which takes place one business day after court order. That translates into about 80MM shares issued.
b) $2MM dollars cash to be wired to CAM on or before February 28, 2013
c) deliver, at the Closing, an aggregate of Six Million Dollars ($6,000,000) in 8% Senior Secured Convertible Debentures (the “Debentures”) ACT will file a registration statement with the SEC for these resale shares.
d)The Company must make quarterly payments under the Debentures on the last day of each calendar quarter commencing on March 31, 2013 in the amount of $473,278. The quarterly payments may, at the option of the Company and subject to the satisfaction of certain conditions, be paid in shares of Common Stock. In such case, the conversion price for such payment will be based on the lesser of (i) the Conversion Price or (ii) 80% of the average of the 10 closing prices immediately prior to the date the quarterly payment is due. To secure its obligations under the Debentures, the Company will grant a security interest in substantially all of the Company’s assets, including its intellectual property, to the Settling Parties
e) Company can repay anytime via cash without penalty and holders can convert at anytime into shares
That is a rough draft of the nuts and bolts of what was filed...thanks
yeah, that's the Aronson case if that's what everyone speaks of here. Having claims dismissed is different than having a lawsuit dismissed. Aronson had several claims dismissed the first time around too but it's still active..thanks north40000, wasn't sure what was being talked about...
and what lawsuit case is slated to be dismissed?
taxinow,
Approx. 50 patents, if your number includes patent applications
then it may be in the ball park..
when the clinical trial site IRB's all approve you will see it there. ACT chose the underlined option below.
So in terms of upcoming milestones for these trials, we've got a total of 36 patients to treat in these three Phase I trials, 12, 12 and 12. But what we really want to do now, and we just actually last weekend had a kind of a getaway with out clinical investigators and members of our Independent Ophthalmic Advisory Board, and what we really wanted to get to was how is the best way for us to go about starting to treat earlier stage patients. Should we hop into a Phase IIA trial and power it with more data and see if we can start looking at what happens when you treat 20/100 or 20/80 patients, or should we just go in and try to change the protocol to include earlier stage patients in our Phase I trial?
believe what you want, no problem..
It has been approved, why would the CEO state "we are going to treat earlier stage patients" if it wasn't? Dr. Elliot from Mass Eye also spoke of the new cutoff this weekend at at a symposium.
I had an e-mail exchange with the DR. and he confirmed that ACT
informed him of the new cutoff.